Literature DB >> 21383714

Despite steep costs, payments for new cancer drugs make economic sense.

Frank R Lichtenberg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21383714     DOI: 10.1038/nm0311-244

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  5 in total

1.  What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?

Authors:  R Scott Braithwaite; David O Meltzer; Joseph T King; Douglas Leslie; Mark S Roberts
Journal:  Med Care       Date:  2008-04       Impact factor: 2.983

2.  Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.

Authors:  Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Francis Giles; Stefan Faderl; Srdan Verstovsek; Guillermo Garcia-Manero; Jianqin Shan; Mary Beth Rios; Richard Champlin; Marcos de Lima; Jorge Cortes
Journal:  Cancer       Date:  2005-05-15       Impact factor: 6.860

3.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

4.  End points and United States Food and Drug Administration approval of oncology drugs.

Authors:  John R Johnson; Grant Williams; Richard Pazdur
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

5.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

Authors:  Hans von der Maase; Lisa Sengelov; James T Roberts; Sergio Ricci; Luigi Dogliotti; T Oliver; Malcolm J Moore; Annamaria Zimmermann; Michael Arning
Journal:  J Clin Oncol       Date:  2005-07-20       Impact factor: 44.544

  5 in total
  4 in total

1.  A catalyst for change: the European cancer Patient's Bill of Rights.

Authors:  Mark Lawler; Thierry Le Chevalier; Martin J Murphy; Ian Banks; Pierfranco Conte; Francesco De Lorenzo; Françoise Meunier; H M Pinedo; Peter Selby; Jean-Pierre Armand; Mariano Barbacid; Michèle Barzach; Jonas Bergh; Gerlind Bode; David A Cameron; Filippo de Braud; Aimery de Gramont; Volker Diehl; Sarper Diler; Sema Erdem; John M Fitzpatrick; Jan Geissler; Donal Hollywood; Liselotte Højgaard; Denis Horgan; Jacek Jassem; Peter W Johnson; Peter Kapitein; Joan Kelly; Sandra Kloezen; Carlo La Vecchia; Bob Löwenberg; Kathy Oliver; Richard Sullivan; Josep Tabernero; Cornelis J Van de Velde; Nils Wilking; Roger Wilson; Christoph Zielinski; Harald Zur Hausen; Patrick G Johnston
Journal:  Oncologist       Date:  2014-02-03

Review 2.  The war on cancer: are we winning?

Authors:  M J Duffy
Journal:  Tumour Biol       Date:  2013-04-09

3.  Estimating the potential annual welfare impact of innovative drugs in use in Switzerland.

Authors:  Matea Pavic; Alena M Pfeil; Thomas D Szucs
Journal:  Front Public Health       Date:  2014-05-20

4.  Understanding drugs in breast cancer through drug sensitivity screening.

Authors:  Katharina Uhr; Wendy J C Prager-van der Smissen; Anouk A J Heine; Bahar Ozturk; Marcel Smid; Hinrich W H Göhlmann; Agnes Jager; John A Foekens; John W M Martens
Journal:  Springerplus       Date:  2015-10-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.